TICKERNERD
Menu
CSBRCSBRHealthcare · Biotechnology

CSBR Stock Forecast: Champions Oncology, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$5.10
0.00% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 11 Sept 2026 — in the lower half.

Market cap
$70.9M
Ticker Nerd rank
28 / 100
Median analyst target
—
Analysts covering
1
Revenue$13.8M+12.0% y/y
Operating income−$521K
Net income−$667K
Free cash flow−$2.2M
Quarterly, 7 quarters to 30 Apr 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.4%
1M
+2.2%
YTD
−26.2%
1Y
−21.1%
From 52W high
−38.6%
From 52W low
+3.7%
$4.92
$8.30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CSBR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Champions Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
79
Quality
76
Volatility
70
Value
56
Growth
33
Issuance
26
Revisions
25
Accruals
24
Momentum
14

Size (79): Smaller than most of the companies we track.

Momentum (14): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CSBR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CSBR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.50$5.00$5.50$6.00$6.50$7.00$7.50$8.00Oct 25Jan 26Apr 26Jul 26CSBR

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Mar 2025Craig-HallumMaintainsBuy$8.00 → $12
12 Dec 2024Craig-HallumMaintainsBuy—
12 Sept 2024Craig-HallumUpgradeBuy—
13 Mar 2024Craig-HallumDowngradeHold—
22 Sept 2023Roth MKMMaintainsBuy—
15 Mar 2021Roth CapitalMaintainsBuy—
18 Nov 2019BenchmarkInitiatesSpeculative Buy—
20 Sept 2019Roth CapitalInitiatesBuy—
24 July 2019Janney CapitalDowngradeNeutral—
24 July 2019Janney Montgomery ScottDowngradeNeutral—
17 July 2018Craig-HallumInitiatesBuy—
15 May 2018Dawson JamesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CSBR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CSBR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Champions Oncology, Inc. returned −21.1% against +17.5% for the S&P 500, dividends included.

CSBR vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Oct 25Jan 26Apr 26Jul 26CSBRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CSBR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Champions Oncology, Inc. (CSBR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
35.9×

Cheaper than 21% of US stocks

Price / sales
1.2×

Cheaper than 65% of US stocks

Price / book
18.0×

Cheaper than 5% of US stocks

EV / EBITDA
203.0×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
12.0%

Higher than 57% of US stocks

Earnings growth (YoY)
12.0%

Higher than 50% of US stocks

Gross margin
50.8%

Higher than 63% of US stocks

Operating margin
−3.8%

Higher than 29% of US stocks

Net margin
−2.0%

Higher than 28% of US stocks

Returns & dividend
Return on equity
−30.0%

Higher than 27% of US stocks

Return on assets
−2.2%

Higher than 37% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Champions Oncology, Inc. (CSBR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Champions Oncology, Inc. has a market value of $70.9M and an enterprise value of $70.6M.

  • Revenue in the twelve months to 30 Apr 2026: $59.4M. The latest quarter grew 12.0% year on year.

  • Net income over the same four quarters: −$1.1M, a −1.9% net margin.

  • Free cash flow in the twelve months to 30 Apr 2026: −$5.0M.

  • Shares outstanding: 13.9M.

  • Trailing P/E: 35.9×; forward P/E: 51.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Champions Oncology, Inc. employs 214 people — $278K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 Apr 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

CSBR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CSBRChampions Oncology, Inc.$70.9M
28
KLRSKalaris Therapeutics, Inc.$70.9M
19
TENXTenax Therapeutics, Inc.$69.6M
22
NRXSNeurAxis, Inc.$71.1M
55
YARWYarrow Bioscience, Inc.$72.1M
53
PLRXPliant Therapeutics, Inc.$72.4M
65
CINGCingulate, Inc.$73.0M
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Champions Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CSBR news & analysis

Champions Oncology, Inc. (CSBR) Q1 2027 Earnings Call Transcript

Seeking Alpha · 10 Sept 2026neutral

Champions Oncology, Inc. held its Q1 2027 earnings call, and the full transcript of the call was published by Seeking Alpha. The item consists of the headline and transcript availability, with no financial details or management commentary included.

Why it matters — A CSBR watcher would care because the Q1 2027 earnings call transcript is now available as a primary source for reviewing the company's latest quarterly performance and management remarks.

Champions Oncology Q1 Earnings Call Highlights

MarketBeat · 10 Sept 2026positive

Champions Oncology reported first-quarter fiscal 2027 results featuring revenue growth, improved margins, and its fifth consecutive quarter of positive adjusted EBITDA. Both its translational oncology services and data licensing businesses contributed to the quarterly performance.

Why it matters — CSBR watchers would note the sustained revenue growth and improving profitability across its core business segments as a sign of continuing financial momentum.

Champions Oncology Reports Revenue of $15.2 Million

Accesswire · 10 Sept 2026positive

Champions Oncology reported first-quarter fiscal 2027 financial results, with revenue of $15.2 million, an 8.8% increase year over year. The company also reported an improved oncology services margin of 51% (up from 43%) and adjusted EBITDA of $671,000, up from $59,000 in the prior-year period.

Why it matters — CSBR watchers would note the company delivered year-over-year revenue growth alongside a material improvement in oncology services margins and adjusted EBITDA, reflecting better study execution and conversion in its core research services business.

CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push

Zacks Investment Research · 30 July 2026neutral

Champions Oncology reported fourth-quarter fiscal 2026 growth with revenue gains, margin improvement, and progress from operational initiatives, though CSBR stock dipped following the earnings announcement.

Why it matters — For CSBR watchers, the results show record revenue growth and operational progress even as the market reacted negatively in the short term.

Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript

Seeking Alpha · 27 July 2026neutral

Seeking Alpha published the transcript of Champions Oncology, Inc.'s Q4 2026 earnings call.

Why it matters — The transcript provides CSBR investors with management's detailed commentary on the company's fourth-quarter financial results and outlook.

FAQ

Frequently asked questions about CSBR stock

Is CSBR stock a buy right now?

Of the 1 analysts covering Champions Oncology, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Champions Oncology, Inc. 28 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CSBR?

As at 11 Sept 2026, Champions Oncology, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).

What is the CSBR stock forecast for 2030?

No analyst covering Champions Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CSBR are extrapolating price history, which says nothing about the business.

How has CSBR stock performed over the past year?

Champions Oncology, Inc. returned -21.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Champions Oncology, Inc. do?

Champions Oncology, Inc. is a biotechnology research services company focused on oncology drug development.

What is the latest news on CSBR?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Champions Oncology, Inc. (CSBR) Q1 2027 Earnings Call Transcript". Champions Oncology, Inc. held its Q1 2027 earnings call, and the full transcript of the call was published by Seeking Alpha. The item consists of the headline and transcript availability, with no financial details or management commentary included.

Company

About Champions Oncology, Inc.

Champions Oncology, Inc. is a biotechnology research services company focused on oncology drug development. Champions Oncology provides preclinical and clinical specialty testing, translational research, and data-driven software solutions that help pharmaceutical and biotechnology companies evaluate cancer therapies. Its core offerings include proprietary tumor models, in vivo and ex vivo research platforms, biomarker analysis, and the TumorGraft technology platform, which supports more personalized approaches to oncology research. The company also offers Lumin Bioinformatics, a software platform that combines research and clinical data for computational cancer analysis and decision-making support. Champions Oncology serves drug developers, research organizations, and medical professionals through technology-enabled services centered on improving the understanding and development of cancer treatments. Headquartered in Hackensack, New Jersey, Champions Oncology operates as a specialized provider within the broader oncology contract research and life sciences tools market.

CEO Mr. Robert Brainin · 214 employees · United States · https://www.championsoncology.com